The UDP-GlcNAc:lysosomal enzyme, N-acetylglucosamine-1-phosphotransferase (GlcNAc-1-PT), is an a 2 b 2 c 2 hexamer that mediates the initial step in the formation of the mannose 6-phosphate targeting signal on newly synthesized lysosomal acid hydrolases. The GNPTAB gene encodes the 1256 amino acid long a/b precursor which is normally cleaved at K928 in the early Golgi by Site-1 protease (S1P). Here, we show that removal of the so-called 'spacer-1 0 domain (residues 86-322) results in cleavage almost exclusively at a second S1P consensus sequence located upstream of K928. In addition, GlcNAc-1-PT lacking spacer-1 exhibits enhanced phosphorylation of several non-lysosomal glycoproteins, while the phosphorylation of lysosomal acid hydrolases is not altered. In view of these effects on the maturation and function of GlcNAc-1-PT, we suggest renaming 'spacer-1 0 the 'regulatory-1 0 domain.
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The cis-Golgi enzyme UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase (GlcNAc-1-PT) performs the initial step in the generation of the mannose 6-phosphate (Man-6-P) targeting signal on lysosomal acid hydrolases. It does so by selectively binding to conformation-dependent protein determinants on these enzymes and catalyzing the transfer of GlcNAc-1-P from UDP-GlcNAc to mannose residues on high mannose-type N-linked glycans of the hydrolases [1] . The GlcNAc is then excised by a second enzyme to generate Man-6-P monoesters, which mediate high affinity binding to Man-6-P receptors (MPRs) in the trans-Golgi network followed by transport of the hydrolases to the endo-lysosomal system [2] . GlcNAc-1-PT is an a 2 b 2 c 2 hexameric protein encoded by two genes. The smaller c subunit is encoded by the GNPTG gene, whereas the a and b subunits are encoded as a single a/b precursor by the GNPTAB gene [3] [4] [5] [6] . Mutations in the GNPTAB gene gives rise to the severe lysosomal storage disorder mucolipidosis II (I-cell disease) or the attenuated mucolipidosis III (pseudo-Hurler polydystrophy), while mutations in the GNPTG gene cause the least severe phenotype known as mucolipidosis III c [7] . Proteolytic cleavage of the human 1256 aa a/b precursor at K928 is mediated by the Site-1 protease (S1P) in the Golgi and this cleavage is essential for catalytic competency of the protein [8] . The a and b subunits harbor four Stealth domains that together form the catalytic core of the protein (Fig. 1A) . The Stealth domains of all eukaryotic GlcNAc-1-PTs are highly conserved and resemble sequences within bacterial genes that encode sugar-phosphate transferases involved in cell wall polysaccharide biosynthesis [9] . The a subunit also contains two Notch modules and a DNA methyltransferase-associated protein (DMAP) interaction domain that we have demonstrated have roles in the specific recognition of protein determinants on lysosomal acid hydrolases, resulting in phosphorylation of their high mannose oligosaccharides [10] . In addition, the a/b precursor has four so-called "spacer" domains of which only one, spacer-2, has been characterized as the c-subunit-binding site [10, 11] . Hitherto, no function has been ascribed to the other spacer regions.
In this study, we investigated the role of spacer-1 in the maturation and function of GlcNAc-1-PT. We found that spacer-1 dictates cleavage of the a/b precursor precisely at K928 by the site-1 protease (S1P) so as to allow for full catalytic activity as removal of spacer-1 results in cleavage at an alternate site (Q882). In addition, deletion of spacer-1 gives rise to an enzyme with enhanced ability to phosphorylate a number of nonlysosomal glycoproteins. Together these findings reveal a novel and unexpected role for spacer-1 in the maturation of the GlcNAc-1-PT a/b precursor and the minimization of phosphorylation of nonlysosomal proteins.
Materials and methods

Cell lines
The GNPTAB À/À HeLa cell line has been described elsewhere [10] . 
DNA constructs
Human GNPTAB-V5/His in pcDNA6 has been described [12] . In order to generate the DS1 and DS1 constructs, 0.5 kb gBlocks gene fragments were synthesized (IDT Inc., Coralville, IA, USA) that encoded either the Dictyostelium discoideum spacer-1 sequence or a Gly/Ser linker sequence together with the human Stealth1 and Stealth 2 sequences. The gBlocks gene fragments were utilized in the first step of a two-step overlap extension PCR to generate the desired constructs. Point mutations were generated by the QuikChange site-directed mutagenesis method and all sequences were confirmed to be correct by DNA sequencing. The LIF cDNA construct was kindly provided by Richard Steet (University of Georgia. Athens, GA, USA), while the Renin-HA cDNA was purchased from Addgene (Cambridge, MA, USA). DNase I, glycopepsinogen, CathD-myc, GLA, and NPC2-myc have been described [10, 13, 14] .
Immunofluorescence microscopy
To visualize the subcellular localization of WT a/b and the various mutants, the different constructs were transfected into GNPTAB À/À HeLa cells using Lipofectamine 3000
(Life Technologies) according to the manufacturer's protocol. Twenty-four hours post-transfection, the cells were fixed and the a/b subunits were detected with mouse anti-V5 monoclonal antibody (Life Technologies 
CI-MPR affinity chromatography and enzyme assays
Soluble bovine CI-MPR was purified from FBS and covalently conjugated to Cyanogen bromide-activated Sepharose 4B (Sigma-Aldrich, St. Louis, MO, USA) as described [15] . Cell extracts from 2-day transfected GNPTAB
À/À
HeLa were incubated with CI-MPR affinity beads, which were washed twice with buffer and then assayed for bound lysosomal enzymes as previously described [12] . The extracts were also assayed for GlcNAc-1-PT activity using the a-methylmannoside (aMM) assay [12] . Enzyme activity was normalized to the total protein concentration of the different cell extracts.
Western blotting
Proteins resolved by SDS/PAGE under reducing conditions were transferred to nitrocellulose membrane and detected with antibodies as described in the figure legends. Equal amount of whole cell extracts were loaded. In several experiments, cell extracts were prepared and equal amounts of lysates were subjected to western blotting for b subunit content to confirm that the constructs were being expressed at comparable levels (not shown).
Immunoprecipitation and oligosaccharide analysis
The proteins of interest secreted into the media were immunoprecipitated, and oligosaccharides isolated and analyzed essentially as described in detail previously [16] . For the CathD-myc, NPC2-myc, and Renin-HA experiments, 20 lL of anti-myc monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or 5 lL of anti-HA monoclonal antibody (Sigma-Aldrich) was prebound to 100 lL Protein G-agarose-PLUS beads (Santa Cruz Biotechnology) prior to immunoprecipitation of labeled proteins from the media. In the case of GLA, DNase I, and LIF, the secreted enzymes were immunoprecipitated with Protein G-agarose-PLUS beads prebound to anti-GLA antibody (Amicus Therapeutics, Cranbury, NJ, USA), and rProteinA-agarose beads (RepliGen, Waltham, MA, USA) prebound to anti-DNase I antibody (SigmaAldrich), or anti-LIF antibody (generously provided by Frederic Blanchard, University of Nantes, Nantes, France).
Immunoprecipitated material was treated with Endo H (NEB, Ipswich, MA, USA) and filtered with Ultracel-10K (EMD Millipore, Billerica, MA, USA). The filtrate containing released neutral and phosphorylated high mannose glycans was treated with mild acid to remove any Nacetylglucosamine residues still attached to the phosphate moieties and applied to a QAE-column matrix to separate the oligosaccharides bearing zero, one, or two Man-6-P residues. The retentate containing Endo H-resistant complex-type oligosaccharides was treated with Pronase (Roche Diagnostics, Indianapolis, IN, USA) and fractionated on ConA-sepharose 4B (GE Healthcare, Pittsburgh, PA, USA) to separate the complex-type glycans from the small amount of high mannose glycans not released by Endo H. The [2-3 H]-mannose content of each fraction was determined and the percent phosphorylation was calculated as described [16] . In all cases, values obtained with the mock transfection were subtracted.
Results
Deletion of spacer-1 results in GlcNAc-1-PT a/b cleavage at an alternate site
As a first-step toward analyzing the function of the spacer-1 domain of the a/b subunit of GlcNAc-1-PT, we performed a sequence alignment between the human protein and that of the lower eukaryote D. discoideum. While it has been demonstrated that the D. discoideum GlcNAc-1-PT is responsible for the transfer of GlcNAc-1-P residues from the donor UDPGlcNAc to specific mannoses on the N-linked high mannose glycans of the acceptor glycoproteins [17] , we noted that the human spacer-1 sequence is 200 aa longer than the short sequence present in D. discoideum (Fig. 1A) , as is the case with all mammalian GlcNAc-1-PT spacer-1 regions for which sequence data are available. This suggested that the mammalian spacer-1 region might play a role not associated with the D. discoideum spacer-1 sequence. To examine this possibility, the 236 aa human spacer-1 sequence was replaced with 29 aa of the D. discoideum sequence at the DNA level and the resulting construct (Fig. 1A,  DS1 ) was transfected into GNPTAB À/À HeLa cells generated by the CRISPR/Cas9 method [10] . Western blot analysis of whole cell extracts expressing the WT and DS1 mutant was performed to determine if replacement of human spacer-1 with the D. discoideum sequence allowed for efficient folding of the mutant protein and its exit from the endoplasmic reticulum (ER) to the cis-Golgi where the a/b precursor is cleaved to the a and b subunits. As shown in Fig. 1B , the mutant protein is indeed expressed well and cleaved, but the bulk of the b subunit product migrated slower on an SDS/PAGE gel than the WT b subunit (Fig. 1B, arrowhead) , indicating that most of the DS1 mutant is being cleaved at an alternate upstream site relative to the K928 cleavage site of the WT protein (Fig. 1B, *) . A small amount of the normal b subunit was also seen with DS1 (Fig. 1B, *) . This raised the question as to whether the alternate cleavage resulting from removal of spacer-1 is due to the same protease, S1P, that cleaves WT a/b precursor at K928, or if a different protease might be involved.
To address this issue, we treated cells with an inhibitor of S1P, the aminopyrrolidineamide PF-429242 [18] . The presence of the inhibitor resulted in the loss of the b subunit formation in both the WT and the DS1 mutant precursors (Fig. 1C) , demonstrating that cleavage at the alternate site is mediated by S1P. If this is the case, an additional consensus S1P cleavage site should exist N-terminal to the original cleavage site. An examination of GlcNAc-1-PT a/b amino acid sequence revealed this to be true with the consensus key arginine residue, R879, occurring at the invariant -4 position, and cleavage postulated to occur at Q882 (Fig. 1D) [19] . Cleavage at Q882 is consistent with the increase in molecular mass of the b subunit seen with DS1 by SDS/PAGE. As expected, mutation of R925 abolishes cleavage of WT a/b precursor at K928 (Fig. 1E, lane 2) . Mutation of R879, on the other hand, did not affect the normal processing of the fulllength a/b precursor at K928 (Fig. 1E, lane 3) , but abolished cleavage at Q882 for the DS1 mutant, as shown by loss of the slower migrating b subunit (Fig. 1E, lane 6) . The trace amount of K928 cleaved b in this case was not affected (Fig. 1E, lane 6 , longer exposure). Mutation of both R925 and R879 resulted in complete loss of b formation (Fig. 1E, lane 7) . These data identify Q882 as a novel S1P cleavage site in the a/b precursor that is rarely utilized except in the absence of spacer-1. Proteolytic processing of the WT a/b precursor at residue K928 is essential for generation of a catalytically active enzyme [4, 12] . This raises the question as to whether cleavage at the Q882 site instead of at K928 also results in an active enzyme. In order to address this question, we tested the activity of the point mutants shown in Fig. 1E toward the simple sugar aMM (Fig. 1F ) and a number of lysosomal enzymes, (Fig. 1G) , both in the context of WT a/b precursor as well as the DS1 mutant. The various constructs were expressed in GNPTAB À/À HeLa cells and 48 h post-transfection, cell extracts were prepared and an aliquot of each was saved to perform the aMM activity assay (Fig. 1F) . The remaining extracts were incubated with beads containing immobilized cationindependent (CI)-MPR to bind the lysosomal enzymes that had been phosphorylated. The beads were washed and assayed for the extent of binding of three lysosomal enzymes as described in Materials & Methods (Fig. 1G ). As shown in Fig. 1F ,G, the R925A mutant in the context of WT a/b precursor had only background activity toward both aMM and lysosomal enzymes, in concordance with previous findings [12] . R879A/WT, on the other hand, exhibited 30% of the activity toward aMM and between 110-125% of the activity toward the three lysosomal enzymes compared to the WT a/b precursor. The basis for the discrepancy observed with the R879A mutant between aMM and lysosomal enzyme activity is not clear at this time. The DS1 mutant exhibited approximately 60% of WT activity toward both aMM (Fig. 1F ) and the panel of lysosomal enzymes (Fig. 1G) . In contrast to the findings with the WT, the R925A mutant in the DS1 background retained almost 20% of WT activity toward aMM, as did the R925A/R879A double mutant (Fig. 1F) . These mutants also exhibited low levels of activity toward the lysosomal enzyme panel (Fig. 1G) . Since the double mutant lacks any proteolytic processing, it demonstrates that in the absence of spacer-1, the uncleaved a/b precursor is partially active. Interestingly, the R879A single mutant retained good activity toward the lysosomal enzyme panel, most likely the result of a combination of the activity of the a/b precursor plus the trace amount of b originating from cleavage at K928 (Fig. 1G) . Since the 236 aa human spacer-1 sequence was replaced with 29 aa of the D. discoideum sequence, we considered the possibility that utilization of the alternate cleavage site is a consequence of introducing the D. discoideum sequence as opposed to the removal of the human spacer-1 sequence. To exclude this, another spacer-1 deletion mutant was constructed in which human spacer-1 was replaced with a 26 aa linker comprising of the small residues Gly and Ser ( Fig. 2A,  DS1) . Dspacer-1 (DS1) behaved in every respect similar to DS1 in that the proteolytic processing mediated by S1P resulted in cleavage for the most part at the new site (Q882) (Fig. 2B) , and DS1 had 40% of WT activity toward aMM (Fig. 2C) . Moreover, the S1P inhibitor, PF-429242, blocked formation of the b subunit with DS1, as it did with WT and the DS1 mutant a/b precursors (Fig. 2D) . We ascertained that both DS and DS1, along with the point mutants shown in Fig. 1E had identical Golgi localization as WT GlcNAc-1-PT (Fig. 3) , ruling out mislocalization of these mutants as a possible cause for the altered cleavage. These results clearly show that the presence of the 236aa spacer-1 sequence in human GlcNAc-1-PT ensures cleavage at K928 instead of Q882.
Deletion of spacer-1 enhances phosphorylation of several nonlysosomal glycoproteins
We next sought to determine the consequence of spacer-1 deletion on the phosphorylation of a number of nonlysosomal glycoproteins that have been shown to acquire low levels of the Man-6-P tag [13, 20, 21] . For this purpose, cDNAs for the nonlysosomal glycoproteins DNase1, Renin, and leukemia inhibitory factor (LIF) were cotransfected along with either WTa/b precursor or the DS1 mutant cDNA, and the degree of phosphorylation quantitated using [2] [3] H]mannoselabeling, immunoprecipitation and direct glycan analysis as described in Material & Methods. In all three cases, the extent of mannose phosphorylation mediated by DS1 was 1.4-2.3-fold higher than that achieved with the WT construct (Fig. 4A) . There was also a substantial increase in the percent oligosaccharides with two Man-6-P residues in the case of DNase1 and Renin. The lysosomal proteins, a-Galactosidase (GLA), Niemann-Pick disease, type C2 (NPC2), and Cathepsin D (CathD), on the other hand, showed a similar degree of phosphorylation irrespective of whether WT or the DS1 construct was cotransfected into the GNPTAB À/À HeLa cells along with expression vectors for the individual enzymes (Fig. 4A) , in agreement with our previous findings with the three endogenous lysosomal enzymes (Fig. 1G ). There was, however, a small increase in the content of glycans with two Man-6-P residues in the case of GLA. Consistent with these data, Renin but not NPC2 displayed increased binding to immobilized CI-MPR when the cDNAs for these two proteins were cotransfected with the DS1 construct compared to the WT a/b precursor (Fig. 4B) . The enhanced binding of Renin likely reflects its increased content of glycans with two Man-6-P residues. Neither glycopepsinogen (GP) nor the membrane glycoproteins, Lamp1 and Lamp2, showed any detectable binding under these conditions (Fig. 4B ). These results demonstrate that spacer-1 limits the extent of phosphorylation of a number of nonlysosomal glycoproteins.
Discussion
The findings presented in this study provide the first evidence for a role of spacer-1 in the biosynthesis and function of the a/b subunits of GlcNAc-1-PT. With regard to biosynthesis, we found that deletion of spacer-1 results in the cleavage of the a/b precursor by the S1P occurring predominantly at Q882 rather than at K928, the normal cleavage site. The reason why S1P cleaves the enzyme at Q882 rather than at K928 H]-mannose, followed by immunoprecipitation of the proteins secreted into the media and determination of the percent N-glycans containing either one (1 PM) or two (2 PM) Man-6-P residues. In all instances, the lysosomal proteins secreted by the cells transfected with plasmids encoding only the lysosomal proteins contain less than 1% phosphorylated glycans [10] . N = 2-5, *P < 0.05; **P < 0.01. in the absence of spacer-1 has not been resolved at this point. One possible explanation is that deletion of spacer-1 leads to a conformational change in the a/b precursor such that the Q882 cleavage site becomes exposed to the S1P while the K928 site becomes inaccessible to this protease. Interestingly, Velho et al. [22] have reported that an in-frame deletion of residues Y937 to M972 of the a/b precursor identified in a mucolipidosis II patient results in the cleavage by S1P at an alternate upstream site within the a subunit. While the new cleavage site was not identified, it is likely to be Q882, with the in-frame deletion leading to a conformational change that exposes the Q882 site.
An alternate but less likely explanation for the altered cleavage site is that spacer-1 directly shields the Q882 site from the action of S1P. The spacer-1 region has a defined structure (PDB ID: 2N6D) and could potentially cover the Q882 site [23] . However, this would not explain why cleavage at the normal K928 site does not occur even when the S1P motif at Q882 is mutated.
Another surprising finding to emerge from these studies is that under some circumstances, cleavage of the a/b precursor is not required for catalytic activity. We first noted this with the DS1 construct that was mutated at both sites to prevent cleavage by S1P. This mutant had about 30% of WT catalytic activity toward aMM. Presumably, there is more than one path to the formation of a catalytically active enzyme. The other major finding in this study is that spacer-1 serves to minimize phosphorylation of the high mannose glycans of a group of nonlysosomal glycoproteins known to be substrates of the transferase. The deletion of spacer-1 led to an increase in the phosphorylation of DNase1, Renin, and LIF by 1.4-2.3-fold over that achieved by the WT enzyme. The basis for this effect awaits further investigation. Nevertheless, the findings presented in this study provide evidence for spacer-1 modulating the maturation and function of GlcNAc-1-PT. In view of this, we propose that the "spacer-1" domain be renamed the "regulatory-1" domain.
